Berkeley Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$308K Hold
2,064
– – 0.06% 156
2026
Q2
$261K Buy
2,064
+11
+0.5% +$1.45K 0.05% 177
2026
Q1
$286K Buy
2,053
+46
+2% +$6.44K 0.07% 153
2025
Q4
$246K Sell
2,007
-16
-0.8% -$1.94K 0.06% 171
2025
Q3
$225K Buy
2,023
+139
+7% +$15.8K 0.05% 169
2025
Q2
$209K Buy
1,884
+5
+0.3% +$532 0.05% 164
2025
Q1
$211K Buy
+1,879
New +$194K 0.06% 162
2020
Q3
– Sell
-7,545
Closed -$580K – 108
2020
Q2
$580K Sell
7,545
-3,132
-29% -$240K 0.36% 48
2020
Q1
$798K Buy
+10,677
New +$738K 0.54% 36
2016
Q1
– Sell
-2,954
Closed -$299K – 115
2015
Q4
$299K Buy
+2,954
New +$307K 0.24% 80

Other funds holding GILD

Berkeley Capital Partners's GILD Position: Q3 2026 in Review

Berkeley Capital Partners held its Gilead Sciences (GILD) position steady in Q3 2026 at 2,064 shares worth $308K. The position accounts for 0.06% of the portfolio, ranked #156.

Berkeley Capital Partners first reported a position in GILD in Q4 2015 and has held it in 10 quarters since. The position peaked at $798K in Q1 2020. 2,357 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Berkeley Capital Partners held 2,064 shares of Gilead Sciences worth $308K as of Q3 2026.
  • Berkeley Capital Partners left its Gilead Sciences share count unchanged in Q3 2026.
  • Gilead Sciences made up 0.06% of Berkeley Capital Partners's portfolio in Q3 2026, its #156 holding.
  • Berkeley Capital Partners first reported a position in Gilead Sciences in Q4 2015 and has held it in 10 quarters since.
  • Berkeley Capital Partners's Gilead Sciences position peaked at $798K in Q1 2020.
  • 2,357 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Berkeley Capital Partners's 13F filing for Q3 2026, filed 12 Nov 2026.